Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
HOME > REGULATORY
REGULATORY
- Ministers Agree on “4.375%” Product Coverage Line for 2023 “Off-Year” Drug Price Revision
December 16, 2022
- Off-Year Re-Pricing Expected to Cover 70% of Listed Products; Special Steps for Unprofitable Drugs, Patented Meds
December 16, 2022
- Insmed’s Arikayce Braces for Price Cuts under CEA Scheme
December 15, 2022
- Finance Minister Hears Out LDP Group’s Emergency Proposal on Off-Year Re-Pricing
December 14, 2022
- Japan to Refit R&D Tax Credit System to Boost Incentive; Lower Minimum Deduction Rate, Variable Cap
December 14, 2022
- Japan to Add Age 12-17 for Moderna Boosters in Free Emergency Program
December 14, 2022
- Japan Govt to Purchase Another 1 Million Courses of Xocova
December 14, 2022
- LDP Committee Insists on Better Handling of Innovative Drugs, Unprofitable Meds in Off-Year Re-Pricing
December 13, 2022
- LDP League, MHLW Discussing to Create Forum to Study SaMD Reimbursement
December 13, 2022
- Paper Retraction Won’t Impact Zolgensma Japan Approval, Data Deleted from Label
December 13, 2022
- Yescarta, Breyanzi Clear Panel Review for Second-Line Use
December 13, 2022
- Japan Panel Recognizes 5 More Deaths Possibly Linked to COVID Jabs, 1st for 20s
December 13, 2022
- Japan’s Diet Enacts Bill to Amend Intractable Disease Law
December 13, 2022
- Add New Evaluation Elements in Granting Launch Premiums: Expert Panel
December 12, 2022
- Market Expansion Re-Pricing Has Gone Overboard with Spillover Rule, Experts Say
December 12, 2022
- Revisit PMP Company Criteria to Support Innovation from Foreign Biotechs: Experts
December 12, 2022
- Experts Call for New Drug Pricing Rule for Innovative Medicines, No Objections Raised
December 12, 2022
- 70% of Listed Meds Likely to Face Off-Year Re-Pricing If Prior Threshold Applied: MHLW
December 12, 2022
- Keytruda Gets Orphan Tag for PMBCL in Japan
December 12, 2022
- First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
ページ
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…